Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
68 hedge funds and large institutions have $161M invested in Evelo Biosciences, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 25 reducing their positions, and 8 closing their positions.
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
3% more funds holding
Funds holding: 66 → 68 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
24% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 25
44% less capital invested
Capital invested by funds: $290M → $161M (-$129M)
78% less call options, than puts
Call options by funds: $49K | Put options by funds: $221K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$1.36M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$844K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$552K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$461K |
| 5 |
Two Sigma Investments
New York
|
+$377K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$6.07M |
| 2 |
Belvedere Trading
Chicago,
Illinois
|
-$284K |
| 3 |
Millennium Management
New York
|
-$270K |
| 4 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
-$243K |
| 5 |
BlackRock
New York
|
-$180K |
EVLO Hedge Fund Activity: Q1 2022 in Review
68 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q1 2022, worth a combined $161M — down 44% from $290M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new EVLO positions and 8 closed out — a net gain of 2 holders — while 19 added to existing stakes and 25 trimmed.
The largest buyer was Group One Trading, adding an estimated $1.36M. The largest seller was Artal Group, exiting entirely with an estimated $6.07M sold.
- 68 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q1 2022, up from 66 in Q4 2021.
- Funds reported $161M of Evelo Biosciences, Inc. Common Stock stock for Q1 2022, down 44% quarter-over-quarter.
- 10 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q1 2022 and 8 closed out, a net change of +2 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q1 2022 was Group One Trading, an estimated $1.36M added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q1 2022 was Artal Group, an estimated $6.07M sold.
Based on aggregated 13F filings for Q1 2022.